Abeona Therapeutics

ABEO · NASDAQ

$4.60+$0.19 (+4.31%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.41

Latest news

Press releaseOct 6, 6:32 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Press releaseSep 24, 5:34 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Press releaseSep 22, 6:13 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NewsSep 18, 7:51 AM ETDylan Berman
Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week
Press releaseSep 18, 7:30 AM ETGlobe Newswire
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
Press releaseSep 16, 7:30 AM ETGlobe Newswire
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Press releaseSep 8, 11:26 PM ETBusiness Wire
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
Press releaseSep 1, 7:44 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Press releaseAug 27, 4:32 PM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NewsAug 13, 11:07 AM ET
Abeona Therapeutics Q2 2026 Earnings Call Transcript
NewsAug 13, 8:05 AM ET
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Press releaseAug 13, 7:30 AM ETGlobe Newswire
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
Press releaseAug 4, 7:30 AM ETGlobe Newswire
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
Press releaseJul 27, 8:30 AM ETPRNewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)
Press releaseJul 21, 7:30 AM ETGlobe Newswire
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
NewsMay 13, 9:51 AM ET
Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
NewsMay 13, 9:31 AM ETDylan Berman
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network
Press releaseMay 13, 7:30 AM ETGlobe Newswire
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
Press releaseMay 11, 8:30 AM ETGlobe Newswire
Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®
Press releaseMay 4, 8:30 AM ETGlobe Newswire
Abeona Therapeutics® Announces Date of First Quarter Financial Results
Press releaseMay 1, 8:30 AM ETGlobe Newswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 17, 7:11 AM ET
Earnings Scheduled For March 17, 2026
NewsNov 12, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 12, 6:11 AM ET
Earnings Scheduled For November 12, 2025
NewsNov 11, 2:03 PM ET
What to Expect from Abeona Therapeutics's Earnings
Press releaseOct 8, 7:30 AM ETGlobe Newswire
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
NewsAug 14, 7:40 AM ET
Abeona Therapeutics Q2 EPS $1.71 Beats $(0.39) Estimate
Press releaseJul 14, 7:00 AM ETPRNewswire
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
NewsMay 27, 8:13 AM ETAvi Kapoor
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseMay 14, 8:07 AM ETGlobe Newswire
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
Press releaseMay 14, 7:30 AM ETGlobe Newswire
Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
NewsApr 30, 4:41 PM ETVandana Singh
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
NewsApr 30, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Abeona Therapeutics Q2 2026 Earnings Call Transcript

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)

Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network

Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

Earnings Scheduled For May 13, 2026

Abeona Therapeutics® Announces Activation of Children's Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Earnings Scheduled For March 17, 2026

12 Health Care Stocks Moving In Wednesday's Intraday Session

Earnings Scheduled For November 12, 2025

What to Expect from Abeona Therapeutics's Earnings

Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy

Abeona Therapeutics Q2 EPS $1.71 Beats $(0.39) Estimate

Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy

PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

12 Health Care Stocks Moving In Wednesday's Intraday Session